Figure 6.

Imatinib and lapatinib cooperate to attenuate BLM-induced lung remodeling. A) Masson's Trichrome staining of paraffin-embedded lung sections from mice challenged with BLM (or saline) for 28 d and treated daily with imatinib and/or lapatinib beginning 15 d following initial BLM insult. Representative photomicrographs are shown (original view ×10). B, C) Quantitative analysis of hydroxyproline contents of lung sections generated from mice treated as in A. D, E) Pixellation scores (expressed as percentage of positive BLM control; ref. 30) quantifying H&E or immunohistochemical staining of lung sections prepared as in A. Data show expression or deposition of smooth muscle actin (SMA), vimentin, fibronectin, collagen I or collagen IV. H&E staining facilitates a direct visualization of collagen. Errors bars = sd. For C and E, both imatinib and lapatinib were used at 50 mg/kg/d. Results support a cooperative therapeutic role of imatinib and lapatinib in attenuating lung remodeling, as evidenced by reduced extracellular matrix production/deposition.